Eiger BioPharmaceuticals, Inc.: M&A transaction — Eiger sells Zokinvy global rights to Sentynl for $45.2M net in bankruptcy sale

Eiger BioPharmaceuticals, Inc.

Closed sale of Zokinvy (lonafarnib) worldwide rights to Sentynl Therapeutics; net base price $45.2M after $0.9M credit.
Bankruptcy Court approved sale on April 23; deal closed May 3, 2024.
Sentynl assumes manufacture and commercialization of Zokinvy.
Company cautions securityholders that trading is highly speculative; holders may face significant or complete loss.
During Chapter 11, Eiger will file monthly financial reports with SEC instead of 10-K/10-Q.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eiger BioPharmaceuticals, Inc. completed a disposition involving Sentynl Therapeutics, Inc. for net base price in the amount of $45.2 million (closed 2024-05-03).

Action: disposition
Counterparty: Sentynl Therapeutics, Inc.
Consideration: net base price in the amount of $45.2 million
Closing: 2024-05-03

Exact text from the filing

the auction of a base price in the amount of $46.1 million less a credit in the amount of $0.9 million for the termination fee resulting in a net base price in the amount of $45.2 million, subject to certain purchase price adjustments, including a reduction of $100,000 per diem if the sale closed after April 24, 2024. At a hearing held on April 23, 2024, the

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-24-134319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.